Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBITDA (2022 - 2025)

Historic EBITDA for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$51.1 million.

  • ARS Pharmaceuticals' EBITDA fell 17414.72% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.4 million, marking a year-over-year decrease of 6538.97%. This contributed to the annual value of $8.2 million for FY2024, which is 11492.79% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' EBITDA stood at -$51.1 million, which was down 17414.72% from -$45.0 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' EBITDA ranged from a high of $49.8 million in Q4 2024 and a low of -$51.1 million during Q3 2025
  • Its 4-year average for EBITDA is -$14.1 million, with a median of -$14.0 million in 2022.
  • Per our database at Business Quant, ARS Pharmaceuticals' EBITDA skyrocketed by 81593.85% in 2024 and then crashed by 25894.55% in 2025.
  • Over the past 4 years, ARS Pharmaceuticals' EBITDA (Quarter) stood at -$14.0 million in 2022, then soared by 50.38% to -$7.0 million in 2023, then surged by 815.94% to $49.8 million in 2024, then tumbled by 202.6% to -$51.1 million in 2025.
  • Its EBITDA stands at -$51.1 million for Q3 2025, versus -$45.0 million for Q2 2025 and -$34.1 million for Q1 2025.